Stabilis

Clindamycin phosphate



鍠喟搧鍚

Biodaclin	澧ㄨタ鍋
Camyda	鍗板害
Cinbiot	澧ㄨタ鍋
Cleocin	鏕熗　冲舀, 濂ュ湴鍒　 缇庶浨
Clinamsa	澧ㄨタ鍋
Clinbac	鍋ヤ鸡姣旆簹, 绉橀曌
Clincina	钁¤悇鑭
Clinda-Saar	寰峰浨
Clindacid	濮斿唴鐕炴媺
Clindacin	椹　澈瑗夸簹
Clindalaf	闐挎牴寤
Clindamicina	鍘勤摐澶氩皵, 鍋ヤ鸡姣旆簹, 澧ㄨタ鍋　 濮斿唴鐕炴媺, 宸磋タ, 鎰忏ぇ鍒　 鏘哄埲, 绉橀曌, 钁¤悇鑭　 瑗跨窬鑭　 闐挎牴寤
Clindamycin	浼婃湕, 鍔犲嬁澶　 濂ュ湴鍒　 寰峰浨, 鎸ｅ■, 娌欑壒闐挎媺浼　 鐕炷吁, 缃楅----灏间簹, 缇庶浨
Clindamycin-Hamel n	寰峰浨
Clindamycine	姣斿埲鏃　 娉曞浨, 绐佸凹鏂　 鑽峰叙
Clindanovag	闐挎牴寤
Clindarix	宸磋タ
Clindasol	寰峰浨
Clindaval	濮斿唴鐕炴媺
Clindazyn	澧ㄨタ鍋
Clindo	娉㈠叙
Clysvic	澧ㄨタ鍋
Daclin	鏘哄埲
Dalacin	涓归害, 浼婃湕, 鍐板矜, 鍔犲嬁澶　 鍖堀墮鍒　 鍗㈡. 銴　 鍗板害, 鍘勤摐澶氩皵, 鍋ヤ鸡姣旆簹, 鍩冨強, 澧ㄨタ鍋　 濮斿唴鐕炴媺, 甯屿厞, 鎰忏ぇ鍒　 鎸ｅ■, 鏂拌タ铍　 鏘哄埲, 姣斿埲鏃　 娌欑壒闐挎媺浼　 娉㈠叙, 婢冲ぇ鍒┼簹, 鐖卞皵鍏　 鐕炷吁, 鐕炷＋, 绐佸凹鏂　 钁　 叙, 鑾卞浨, 鑽峰叙, 闐胯仈閭　 椹　 澈瑗夸簹
Dalacine	娉曞浨, 绐佸凹鏂
Daladic	浼婃湕

Dalcinex	鍗板害
Damclid	鍗板害
Damicin	鍋ヤ鸡姣旆簹, 澧メタ鍋
Damicine	鍋ヤ鸡姣旆簹
Dolarclin	鍋ヤ鸡姣旆簹
Euroclin	鍘勤摐澶氩皵, 鍋ヤ鸡姣旆簹
Gynasafe	鍗板害
Indamid	澧メタ鍋
Klimicin	娉㈠叙
Klindan	鏣煽　冲舌
Klindaver	鏣煽　冲舌
Lanacine	濂ュ湴鍒
Lincocin	椹　澈瑗夸簹
Lincosa	椹　澈瑗夸簹
Meneklin	鏣煽　冲舌
Sobelin	寰峰浣
Tidact	椹　澈瑗夸簹

婧舵恫绋冲畾鎬

		15 mg/ml	22掳C		91			80
		15 mg/ml	4掳C		91			80
		6 , 9 & 12 mg/ml	-10掳C		56			566
		6 , 9 & 12 mg/ml	25掳C		16			566
		6 , 9 & 12 mg/ml	4掳C		32			566
		9 mg/ml	24掳C		24			421
		9 mg/ml	25掳C		48			418
		9 mg/ml	25掳C		48			565
		9 & 12 mg/ml	25掳C		48			432
		6 , 9 & 12 mg/ml	-10掳C		56			566
		6 , 9 & 12 mg/ml	25掳C		16			566
		6 , 9 & 12 mg/ml	4掳C		32			566
		9 mg/ml	24掳C		24			421
		9 mg/ml	25掳C		48			418
		9 mg/ml	25掳C		48			565

		9 & 12 mg/ml	25摴C		48				432
PVC		6 , 9 & 12 mg/ml	-10摴C		56				566
PVC		6 , 9 & 12 mg/ml	25摴C	?	16				566
PVC		6 , 9 & 12 mg/ml	4摴C		32				566
PVC		6 & 12 mg/ml	-10摴C		68				567
PVC		6 & 12 mg/ml	25摴C	?	22				567
PVC		6 & 12 mg/ml	5摴C		54				567
PVC		9 mg/ml	-20摴C		28				565
PVC		9 mg/ml	24摴C		24				421
PVC		6 mg/ml	-20摴C		30				575
PVC		6 , 9 & 12 mg/ml	-10摴C		56				566
PVC		6 , 9 & 12 mg/ml	25摴C	?	16				566
PVC		6 , 9 & 12 mg/ml	4摴C		32				566
PVC		6 & 12 mg/ml	-10摴C		68				567
PVC		6 & 12 mg/ml	25摴C	?	22				567
PVC		6 & 12 mg/ml	5摴C		54				567
PVC		9 mg/ml	-20摴C		28				565
PVC		9 mg/ml	24摴C		24				421
PE		3 mg/ml	22摴C		24				1067
PE		3 mg/ml	4摴C		24				1067
PE		3 mg/ml	22摴C		24				1067
PE		3 mg/ml	4摴C		24				1067
EVA		6 & 12 mg/ml	23摴C		7				1815
EVA		6 & 12 mg/ml	4摴C		30				1815
		150 mg/ml	22摴C-23摴C		48				639
		60 mg/ml	25摴C		48				644
PI		2 & 12 mg/ml	25摴C	?	24				604
PI		2 & 12 mg/ml	4摴C		10				604
?		9,5 mg/ml	2-8摴C	?	49				4622
?		9,5 mg/ml	25摴C	?	24				4622
?		9,5 mg/ml	2-8摴C	?	47				4619
?		9,5 mg/ml	25摴C	?	24				4619

娣峰惬鐗┾ ŭ 瀹氣

		12 mg/ml	23掳C		Cefpirome sulfate : 50 mg/ml	8	280
		9 mg/ml	24掳C		Cefotaxime sodium : 20 mg/ml	24	421
		9 mg/ml	24掳C		Netilmicin sulfate : 3 mg/ml	24	421
		12 mg/ml	25掳C		Ceftriaxone disodium : 20 mg/ml	8	432
		9 mg/ml	25掳C		Cefazolin sodium : 10 mg/ml Gentamicin sulfate : 0,8 mg/ml	12	695
		9 mg/ml	25掳C		Ceftizoxime sodium : 20 mg/ml	24	418
		9 mg/ml	25掳C		Ceftazidime : 20 mg/ml	48	432
		60 mg/ml	25掳C		Aztreonam : 200 mg/ml	48	644
		9 mg/ml	25掳C		Aztreonam : 20 mg/ml	48	432
		9 mg/ml	25掳C		Piperacillin sodium : 40 mg/ml	48	432
		9 mg/ml	25掳C		Cefoxitin sodium : 20 mg/ml	48	418
		9 mg/ml	25掳C		Cefamandole nafate : 10 mg/ml	48	418
		9 mg/ml	25掳C		Cefazolin sodium : 10 mg/ml	48	418
		12 mg/ml	25掳C		Cefoperazone sodium : 20 mg/ml	48	644
		12 mg/ml	25掳C		Cefonicid sodium : 10 mg/ml	48	644
		9 mg/ml	25掳C		Cefuroxime sodium : 15 mg/ml	48	644
		12 mg/ml	23掳C		Cefpirome sulfate : 50 mg/ml	8	280
		9 mg/ml	24掳C		Cefotaxime sodium : 20 mg/ml	24	421
		9 mg/ml	24掳C		Netilmicin sulfate : 3 mg/ml	24	421
		12 mg/ml	25掳C		Ceftriaxone disodium : 20 mg/ml	1	432
		9 mg/ml	25掳C		Cefazolin sodium : 10 mg/ml Gentamicin sulfate : 0,8 mg/ml	1	695
		9 mg/ml	25掳C		Ceftazidime : 20 mg/ml	24	432
		9 mg/ml	25掳C		Ceftizoxime sodium : 20 mg/ml	48	418
		9 mg/ml	25掳C		Aztreonam : 20 mg/ml	48	432
		9 mg/ml	25掳C		Piperacillin sodium : 40 mg/ml	48	432
		9 mg/ml	25掳C		Cefoxitin sodium : 20 mg/ml	48	418
		9 mg/ml	25掳C		Cefamandole nafate : 10 mg/ml	48	418
		9 mg/ml	25掳C		Cefazolin sodium : 10 mg/ml	48	418
		12 mg/ml	25掳C		Cefoperazone sodium : 20 mg/ml	48	644

		12 mg/ml	25摮C		Cefonicid sodium : 10 mg/ml	48	644
		9 mg/ml	25摮C		Cefuroxime sodium : 15 mg/ml	48	644
	RL	12 mg/ml	23摮C		Cefpirome sulfate : 50 mg/ml	8	280
	0.45	12 mg/ml	23摮C		Cefpirome sulfate : 50 mg/ml	8	280
	∅	6 mg/ml	25摮C	?	Ofloxacin : 2 mg/ml	48	889
PVC		9 mg/ml	-20摮C		Tobramycin sulfate : 1,2 mg/ml	28	565
PVC		9 mg/ml	-20摮C		Gentamicin sulfate : 1,2 mg/ml	28	565
PVC		3 & 6 mg/ml	22摮C-23摮C	?	Aztreonam : 10 & 20 mg/ml	48	419
PVC		9 mg/ml	24摮C		Cefotaxime sodium : 20 mg/ml	24	421
PVC		9 mg/ml	24摮C		Netilmicin sulfate : 3 mg/ml	24	421
PVC		9 mg/ml	25摮C	?	Amikacin sulfate : 4 mg/ml	48	565
PVC		3 & 6 mg/ml	4摮C		Aztreonam : 10 & 20 mg/ml	7	419
PVC		9 mg/ml	-20摮C		Tobramycin sulfate : 1,2 mg/ml	14	565
PVC		9 mg/ml	-20摮C		Gentamicin sulfate : 1,2 mg/ml	28	565
PVC		3 & 6 mg/ml	22摮C-23摮C	?	Aztreonam : 10 & 20 mg/ml	48	419
PVC		9 mg/ml	24摮C		Cefotaxime sodium : 20 mg/ml	24	421
PVC		9 mg/ml	24摮C		Netilmicin sulfate : 3 mg/ml	24	421
PVC		6 mg/ml	25摮C		Gentamicin sulfate : 5 mg/ml	24	423
PVC		9 mg/ml	25摮C	?	Amikacin sulfate : 4 mg/ml	48	565
PVC		3 & 6 mg/ml	4摮C		Aztreonam : 10 & 20 mg/ml	7	419
PP		90 mg/ml	22摮C-23摮C		Gentamicin sulfate : 30 mg/ml	48	639
PP		90 mg/ml	22摮C-23摮C		Amikacin sulfate : 190 mg/ml	48	639

褰卞摳绋冲畾鎬 x 殑鍥犵礌

	PH >7				3526

鍏煎　鎬

		Clindamycin phosphate : 12 mg/ml Aciclovir sodium : 5 mg/ml		336
		Clindamycin phosphate : 10 mg/ml Allopurinol sodium : 3 mg/ml		307

		Clindamycin phosphate : 10 mg/ml Amifostine : 10 mg/ml		3
		Clindamycin phosphate Amikacin sulfate		3526
		Clindamycin phosphate : 9 mg/ml Amikacin sulfate : 4 mg/ml		565
		Clindamycin phosphate : 9 mg/ml Amikacin sulfate : 4 mg/ml		565
		Clindamycin phosphate Amikacin sulfate		3526
		Clindamycin phosphate : 90 mg/ml Amikacin sulfate : 75 mg/ml		639
		Clindamycin phosphate Aminophylline		3526
		Clindamycin phosphate : 6 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Clindamycin phosphate : 6 mg/ml Amiodarone hydrochloride : 4 mg/ml		385
		Clindamycin phosphate : 150 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Clindamycin phosphate : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Clindamycin phosphate Ampicillin sodium		3526
		Clindamycin phosphate		3526
		Clindamycin phosphate Amobarbital sodium		3526
		Clindamycin phosphate : 10 mg/ml Amsacrine : 1 mg/ml		253
		Clindamycin phosphate : 10 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Clindamycin phosphate : 9 mg/ml Atosiban : 0,75 mg/ml		4642
		Clindamycin phosphate : 6 mg/ml Aztreonam : 10 mg/ml		419
		Clindamycin phosphate : 9 mg/ml Aztreonam : 20 mg/ml		432
		Clindamycin phosphate : 60 mg/ml Aztreonam : 200 mg/ml		644
		Clindamycin phosphate Aztreonam		3526
		Clindamycin phosphate : 3 mg/ml Aztreonam : 10 mg/ml		419
		Clindamycin phosphate Aztreonam		3526
		Clindamycin phosphate : 24 mg/ml		3379
		Clindamycin phosphate : 30 mg/ml Azithromycine : 2 mg/ml		1800
		Clindamycin phosphate : 3 mg/ml		1055
		Clindamycin phosphate : 6 mg/ml Aztreonam : 20 mg/ml		419

		Clindamycin phosphate : 3 mg/ml Aztreonam : 20 mg/ml		419
		Clindamycin phosphate : 3 mg/ml Aztreonam : 20 mg/ml		419
		Clindamycin phosphate : 6 mg/ml Aztreonam : 20 mg/ml		419
		Clindamycin phosphate : 10 mg/ml Aztreonam : 40 mg/ml		99
		Clindamycin phosphate : 3 mg/ml Aztreonam : 10 mg/ml		419
		Clindamycin phosphate : 6 mg/ml Aztreonam : 10 mg/ml		419
		Clindamycin phosphate : 9 mg/ml Aztreonam : 20 mg/ml		432
		Clindamycin phosphate : 10 mg/ml Bivalirudin : 5 mg/ml		1713
		Clindamycin phosphate : 150 mg/ml Caffeine : 10 mg/ml	∅	3964
		Clindamycin phosphate Calcium gluconate		3644
		Clindamycin phosphate Calcium gluconate		3526
		Clindamycin phosphate Calcium gluconate		4964
		Clindamycin phosphate : 10 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Clindamycin phosphate : 60 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Clindamycin phosphate : 9 mg/ml Cefamandole nafate : 10 mg/ml		418
		Clindamycin phosphate Cefamandole nafate		3526
		Clindamycin phosphate : 9 mg/ml Cefamandole nafate : 10 mg/ml		418
		Clindamycin phosphate Cefamandole nafate		3526
		Clindamycin phosphate : 9 mg/ml Cefazolin sodium : 10 mg/ml		418
		Clindamycin phosphate Cefazolin sodium		3526
		Clindamycin phosphate : 9 mg/ml Cefazolin sodium : 10 mg/ml		418
		Clindamycin phosphate : 0,25 & 6 mg/ml Cefepime dihydrochloride : 4 & 40 mg/ml		3548
		Clindamycin phosphate : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Clindamycin phosphate : 12 mg/ml Cefoperazone sodium : 20 mg/ml		644
		Clindamycin phosphate	NaH CO3	3526
		Clindamycin phosphate : 12 mg/ml Cefonicid sodium : 10 mg/ml		644
		Clindamycin phosphate : 10 mg/ml		301

	✓	Clindamycin phosphate Cefazolin sodium	◆	3526
	✓	Clindamycin phosphate : 0,25 & 6 mg/ml Cefepime dihydrochloride : 4 & 40 mg/ml	▲	3548
	✓	Clindamycin phosphate : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	▲	4528
	✓	Clindamycin phosphate : 12 mg/ml Cefonicid sodium : 10 mg/ml	◆	644
	✓	Clindamycin phosphate : 12 mg/ml Cefoperazone sodium : 20 mg/ml	▲	644
	✓	Clindamycin phosphate : 150 mg/ml		999
	✓	Clindamycin phosphate Cefotaxime sodium	◆	3526
	✓	Clindamycin phosphate : 9 mg/ml Cefotaxime sodium : 20 mg/ml	◆	421
	✓	Clindamycin phosphate : 9 mg/ml Cefotaxime sodium : 20 mg/ml	▲	421
	✓	Clindamycin phosphate Cefotaxime sodium	▲	3526
	✓	Clindamycin phosphate Cefoxitin sodium	▲	3526
	✓	Clindamycin phosphate : 9 mg/ml Cefoxitin sodium : 20 mg/ml	◆	418
	✓	Clindamycin phosphate : 9 mg/ml Cefoxitin sodium : 20 mg/ml	▲	418
	✓	Clindamycin phosphate Cefoxitin sodium	◆	3526
	✓	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml	▲	280
	✓	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
	✓	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml	◆	280
	✓	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
	✓	Clindamycin phosphate : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	✓	Clindamycin phosphate Ceftazidime	◆	3526
	✓	Clindamycin phosphate : 9 mg/ml Ceftizoxime sodium : 20 mg/ml	▲	418
	✓	Clindamycin phosphate Ceftizoxime sodium	◆	3526
	✓	Clindamycin phosphate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	▲	2269
	✓	Clindamycin phosphate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	◆	2269
	✓	Clindamycin phosphate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	✓	Clindamycin phosphate : 5,77 mg/ml		4440
	✓	Clindamycin phosphate : 1.2 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml	◆	1201

		Clindamycin phosphate : 1.2 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml		1201
		Clindamycin phosphate : 7 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Clindamycin phosphate : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Clindamycin phosphate : 150 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Clindamycin phosphate : 10 mg/ml Docetaxel : 0.9 mg/ml		1754
		Clindamycin phosphate : 10 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
		Clindamycin phosphate : 10 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Clindamycin phosphate : 9 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Clindamycin phosphate : 9 mg/ml Fentanyl citrate : 50 碌g/ml		63
		Clindamycin phosphate : 10 mg/ml		3967
		Clindamycin phosphate : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Clindamycin phosphate : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Clindamycin phosphate : 9 mg/ml Ceftazidime : 20 mg/ml		432
		Clindamycin phosphate Ceftazidime		3526
		Clindamycin phosphate : 9 mg/ml Ceftazidime : 20 mg/ml		432
		Clindamycin phosphate : 10 mg/ml		1415
		Clindamycin phosphate : 9 mg/ml Ceftizoxime sodium : 20 mg/ml		418
		Clindamycin phosphate Ceftizoxime sodium		3526
		Clindamycin phosphate : 12 mg/ml Ceftriaxone disodium : 20 mg/ml		432
		Clindamycin phosphate Ceftriaxone disodium		3526
		Clindamycin phosphate : 12 mg/ml Ceftriaxone disodium : 20 mg/ml		432
		Clindamycin phosphate : 9 mg/ml Cefuroxime sodium : 15 mg/ml		644
		Clindamycin phosphate : 9 mg/ml Cefuroxime sodium : 15 mg/ml		644
		Clindamycin phosphate : 7 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
		Clindamycin phosphate Ciprofloxacin lactate		3526
		Clindamycin phosphate : 10 mg/ml Dexmedetomidine : 4 碌g/ml		1712
		Clindamycin phosphate : 12 & 150 mg/ml Diltiazem hydrochloride : 5 mg/ml		198

		Clindamycin phosphate Dimenhydrinate		2087
		Clindamycin phosphate : 9 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Clindamycin phosphate : 10 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Clindamycin phosphate : 10 mg/ml Fenoldopam mesylate : 80 碌g/ml		1803
		Clindamycin phosphate : 10 mg/ml Filgrastim : 30 碌g/ml		244
		Clindamycin phosphate : 12 mg/ml Fluconazole : 2 mg/ml		256
		Clindamycin phosphate : 24 mg/ml Fluconazole : 2 mg/ml		496
		Clindamycin phosphate : 10 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Clindamycin phosphate : 12 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Clindamycin phosphate : 24 mg/ml Foscarnet sodium : 24 mg/ml		73
		Clindamycin phosphate : 12 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Clindamycin phosphate : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Clindamycin phosphate Gentamicin sulfate		3526
		Clindamycin phosphate : 90 mg/ml Gentamicin sulfate : 12 mg/ml		639
		Clindamycin phosphate : 6 mg/ml Gentamicin sulfate : 0.67 mg/ml		423
		Clindamycin phosphate Gentamicin sulfate		3526
		Clindamycin phosphate : 10 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Clindamycin phosphate : 12 mg/ml Heparin sodium : 50 UI/ml		317
		Clindamycin phosphate : 10 mg/ml Hetastarch : 60 mg/ml		1721
		Clindamycin phosphate : 12 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Clindamycin phosphate Idarubicin hydrochloride		3526
		Clindamycin phosphate : 12 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Clindamycin phosphate : 150 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Clindamycin phosphate : 9 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Clindamycin phosphate : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Clindamycin phosphate : 150 mg/ml Levofloxacine : 5 mg/ml		1072

		Clindamycin phosphate : 10 mg/ml Linezolid : 2 mg/ml	∅	1925
		Clindamycin phosphate Magnesium chloride		5012
		Clindamycin phosphate Magnesium sulfate		3838
		Clindamycin phosphate : 12 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml	◆	1047
		Clindamycin phosphate Magnesium sulfate		3526
		Clindamycin phosphate : 10 mg/ml Melphalan : 0.1 mg/ml	▲	169
		Clindamycin phosphate : 150 mg/ml Meropenem : 50 mg/ml	●	4319
		Clindamycin phosphate Methohexital sodium		3526
		Clindamycin phosphate : 10 mg/ml Metronidazole : 5 mg/ml	∅	1035
		Clindamycin phosphate Metronidazole		3594
		Clindamycin phosphate : 9 mg/ml Midazolam hydrochloride : 1 mg/ml	◆	176
		Clindamycin phosphate : 12 mg/ml Morphine sulfate : 1 mg/ml	◆	405
		Clindamycin phosphate : 150 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Clindamycin phosphate : 150 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Clindamycin phosphate Netilmicin sulfate	▲	3526
		Clindamycin phosphate : 9 mg/ml Netilmicin sulfate : 3 mg/ml	◆	421
		Clindamycin phosphate : 9 mg/ml Netilmicin sulfate : 3 mg/ml	▲	421
		Clindamycin phosphate Netilmicin sulfate	◆	3526
		Clindamycin phosphate : 9 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	▲	1490
		Clindamycin phosphate : 9 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	◆	1490
		Clindamycin phosphate : 6 mg/ml Ofloxacin : 2 mg/ml	∅	889
		Clindamycin phosphate : 10 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Clindamycin phosphate : 12 mg/ml Oritavancin : 0.8 >>2 mg/ml	◆	3152
		Clindamycin phosphate Pantoprazole sodium		2090
		Clindamycin phosphate : 150 mg/ml Paracetamol : 10 mg/ml		4742
		Clindamycin phosphate : 10 mg/ml Paracetamol : 10 mg/ml	∅	3571

		Clindamycin phosphate : 10 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Clindamycin phosphate Pentobarbital sodium		3526
		Clindamycin phosphate : 12 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Clindamycin phosphate Phenobarbital sodium		3526
		Clindamycin phosphate Phenytoin sodium		3526
		Clindamycin phosphate : 18 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Clindamycin phosphate Piperacillin sodium		3526
		Clindamycin phosphate Piperacillin sodium		3526
		Clindamycin phosphate : 9 mg/ml Piperacillin sodium : 40 mg/ml		432
		Clindamycin phosphate : 9 mg/ml Piperacillin sodium : 40 mg/ml		432
		Clindamycin phosphate : 10 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Clindamycin phosphate : 150 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Clindamycin phosphate Sodium bicarbonate		3526
		Clindamycin phosphate : 12 mg/ml Temocilline : 83.33 mg/ml		2231
		Clindamycin phosphate : 10 mg/ml Teniposide : 0.1 mg/ml		905
		Clindamycin phosphate Thiopental sodium		3526
		Clindamycin phosphate		3526
		Clindamycin phosphate : 10 mg/ml Propofol : 10 mg/ml		300
		Clindamycin phosphate Ranitidine hydrochloride		3526
		Clindamycin phosphate : 10 mg/ml Remifentanil hydrochloride : 25 & 250 碌g/ml		59
		Clindamycin phosphate : 10 mg/ml Sargramostim : 10 碌g/ml		335
		Clindamycin phosphate : 12 mg/ml Tacrolimus : 1000 碌g/ml		479
		Clindamycin phosphate : 12 mg/ml Theophylline : 4 mg/ml		317
		Clindamycin phosphate : 150 mg/ml Thiopental sodium : 25 mg/ml		3767
		Clindamycin phosphate : 10 mg/ml Thiotepa : 1 mg/ml		249
		Clindamycin phosphate Tobramycin sulfate		3526

		Clindamycin phosphate : 90 mg/ml Tobramycin sulfate : 12 mg/ml		639
		Clindamycin phosphate Tobramycin sulfate		3526
		Clindamycin phosphate : 6 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
		Clindamycin phosphate : 1.2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Clindamycin phosphate : 1.2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Clindamycin phosphate : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Clindamycin phosphate : 12 mg/ml Zidovudine : 4 mg/ml		337

鑿×嵂闔斿緞

寮曠敤鏂囝寮

	绉嶇被	鍑虹增鑭
3	鏂囝寮	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	鏂囝寮	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	鏂囝寮	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	鏂囝寮	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
80	鏂囝寮	Nahata MC, Morosco RS, Hipple TF. Stability of cimetidine hydrochloride and of clindamycin phosphate in water for injection stored in glass vials at two temperatures. Am J Hosp Pharm 1993 ; 50: 2559-2561.
81	鏂囝寮	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	鏂囝寮	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	鏂囝寮	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

169	鏂园寮	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	鏂园寮	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	鏂园寮	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	鏂园寮	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	鏂园寮	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	鏂园寮	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	鏂园寮	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	鏂园寮	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	鏂园寮	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
280	鏂园寮	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
299	鏂园寮	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	鏂园寮	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	鏂园寮	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	鏂园寮	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
317	鏂园寮	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	鏂园寮	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	鏂园寮	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.

336	鑑固奈	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	鑑固奈	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	鑑固奈	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	鑑固奈	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.
386	鑑固奈	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	鑑固奈	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
418	鑑固奈	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
419	鑑固奈	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and clindamycin phosphate. Am J Hosp Pharm 1985 ; 42: 1984-1986.
421	鑑固奈	Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843.
423	鑑固奈	Mansur JM, Abramowitz PW, Lerner SA, Smith RB, Townsend RJ. Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am J Hosp Pharm 1985 ; 42: 332-335.
432	鑑固奈	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
434	鑑固奈	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
479	鑑固奈	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	鑑固奈	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	鑑固奈	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	鑑固奈	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.

565	鏂园寮	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.
566	鏂园寮	Porter WR, Johnson CA, Cohon MS, Gillespie W. Compatibility and stability of clindamycin phosphate with intravenous fluids. Am J Hosp Pharm 1983 ; 40: 91-94.
567	鏂园寮	Das Gupta V, Parasrampuria J, Bethea C, Wright W. Stability of clindamycin phophate in dextrose and saline solutions. Can J Hosp Pharm 1989 ; 42: 109-112.
575	鏂园寮	Holmes CJ, Ausman RK, Kundsin RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
604	瀹為獙瀹	Stabilit茅 des m茅dicaments dans l'Intermate庐 SV50, 100, 200 Baxter 1998
639	鏂园寮	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
644	鏂园寮	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
695	鏂园寮	Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. Drug Intell Clin Pharm 1988 ; 22: 873-875.
889	鏂园寮	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905	鏂园寮	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	鏂园寮	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	鏂园寮	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	鏂园寮	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	鏂园寮	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1055	鏂园寮	Faragos S. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. Can J Hosp Pharm 1983 ; 36: 43-52.
1057	鏂园寮	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.

1067	鑑固寮	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1072	鑑固寮	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	鑑固寮	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1201	鑑固寮	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	鑑固寮	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	鑑固寮	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	鑑固寮	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	鑑固寮	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	鑑固寮	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	鑑固寮	Trissel LA, Saenz CA, Williams KY, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	鑑固寮	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	鑑固寮	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	鑑固寮	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	鑑固寮	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	鑑固寮	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1802	鑑固寮	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	鑑固寮	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1815	鏂园寮	Xu QA, Trissel LA. Stability of clindamycin phosphate in autodose infusion system bags. Int J Pharm Compound 2003 ; 7, 2: 149-151.
1925	鏂园寮	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	鏂园寮	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	鏂园寮	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2002	鏂园寮	Abanmy NO, Zaghloul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2087	鏂园寮	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	鏂园寮	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	鏂园寮	Pelletier E, Forest JM, Hildgen P. Compatibilit茅 de la k茅tamine injectable lors de l鈥檚dministration en d茅riv茅 avec d鈥檚utres m茅dicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	鏂园寮	Jacquet R, Lions C, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	鏂园寮	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	鏂园寮	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2269	鏂园寮	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	鏂园寮	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	鏂园寮	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	鏂园寮	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilit茅 physique par 茅valuation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	鏂园寮	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.

3379	鏂园寮	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	鏂园寮	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilit茅 physique de la naloxone avec d鈥檚utres m茅dicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3526	瀹為獙瀹	Clindamycin (Dalacin庐) - Summary of Product Characteristics Pharmacia 2010
3548	瀹為獙瀹	Cefepime (Maxipime庐) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3571	鏂园寮	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3594	瀹為獙瀹	Metronidazole (Flagyl庐) - Summary of Product Characteristics Zentiva 2013
3644	瀹為獙瀹	Calcium gluconate庐 - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3766	鏂园寮	Forrest J.M, Hildgen P. Compatibilit茅 de l鈥檚c茅tylcyst茅ine injectable lors de son administration en Y avec d鈥檚utres m茅dicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	鏂园寮	Forrest J.M, Hildgen P. Compatibilit茅 par 茅valuation visuelle du thiopental injectable lors de son administration en Y avec des m茅dicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	娴锋姤	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. 脡tude de la compatibilit茅 physico-chimique du phloroglucinol injectable durant les m茅langes au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	鏂园寮	Boudi S, Roy H, Forest JM, Leclair G. Compatibilit茅 physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres m茅dicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3838	瀹為獙瀹	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3964	鏂园寮	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilit茅 du citrate de caf茅ine injectable avec plusieurs autres m茅dicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	鏂园寮	Staven V, Herra I, Wang S, Gr枚nlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
4319	鏂园寮	Lessard J-J, Caron E, Sch茅rer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4440	鏂园寮	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	鏂园寮	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

4619	璩ｉ嘶鑩ｙ 坉瀵冖　瀹	Simms D, Roberts J, Rigge D. Stability Study for Clindamycin 9.52mg/mL in 5.0% w/v Glucose 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4622	璩ｉ嘶鑩ｙ 坉瀵冖　瀹	Simms D, Roberts J, Rigge D. Stability Study for Clindamycin 9.52mg/mL in 0.9% w/v Sodium Chloride 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4642	娴锋姤	Larossa garcia M, Jimenez-Lozano I, Boix-Montan茅s A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. SEFH Congress (Virtual) October 2021 2021
4742	鏂园寮	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilit茅 physique de l鈥檟c茅taminoph猫ne injectable avec 102 autres m茅dicaments lors d鈥檇ne administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4964	瀹為獙瀹	GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - R茅sum茅 des caract茅ristiques du produit. B BRAUN MELSUNGEN AG 2019
5012	瀹為獙瀹	CHLORURE DE MAGNESIUM 10 POUR CENT (1 g/10 ml) LAVOISIER, solution injectable (I.V.) en ampoule - R茅sum茅 des caract茅ristiques du produit. LABORATOIRES CHAIX ET DU MARAIS 2018

瀛楀吁

	鎒榎敓绱
	鍠喟搧鍚
	瀹瑰檠
	娴撳害
	淇濆瓨
	鏨熺墿浠胯＝钑
	寮曠敤鏂囝寮
	娉ㄥ皪鏨ㄦ按
	鐧藉ぉ
	鏃犯壒娈娴　姹
	灏忔棣
PVC	鑱氣隘涔欑儻
EVA	涔欑儻涔欓吁涔欑儻閰
PI	鑱氯暟鎴婁簩鐑　綀鎬ч珨
	娣峰悎鐧┼ǔ瀹氣
	鍒喟瓙
0.45	NaCl 0.45%
	褰卞摬绋冲畾鎬x殑鍥犯礌
	鍒嗚B
	鍏煎
	涓嶾浙瀹
	涓　灏忔棵娓炬縼
	鑲犲　钀ュ吁锛埬簩绉嶈贩鍚堛墿锛
	鑲犲　钀ュ吁锛堝惈鑴傝偑锛
	鍖桋　涓嶾---瀹氣
	1灏忔棵寰屾灘鍑
	2灏忔棵寰岏嚭鐨炬矇婢
	闈欒剞杈撳恫
	鑲岁軌鍐
	瀛楀吁

	娉ㄥ皪娑
	婧舵恫绋冲畾鎬
	鍒喟瓙
	娓┼害
	绌┼畾鎸佺簩鏘傞枔
	鏋溦浘鐨勦暩鐔
	鍈荤拑
	閬垮厜
	NaCl 0,9%
	鐔
	钁¤悇绯　%
PE	鑱氢篁鐑
	娉ㄥ皪鍣　鑱氢笝鐑
	涓嶶
	婧跺墏
RL	Ringer涔抽吁婧舵恫
	鏃
	璇卞
	鐔煎　鎬
	绔嬪嵇娌颈
	鏈ｆ害瀹氣殑涓嵇吋瀹规
△pH >±1	淇　敼pH> 1 pH鍠　綅
NaH CO3	NaHCO3
	鏨㈢敓姘ｆ场
	鍕瑰畾婧舵恫
	绔嬪嵇娓炬縼
	鏨ｘ嵂閫斿緞
	鎸佺画杈撳恫
	寮曠敤鏂囝寮